These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11395131)

  • 1. Antithrombin activity of an algal polysaccharide.
    Trento F; Cattaneo F; Pescador R; Porta R; Ferro L
    Thromb Res; 2001 Jun; 102(5):457-65. PubMed ID: 11395131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombin inhibitors and anti-coagulants on thrombin-induced embolisation in rabbit cranial vasculature.
    Liu JT; Paul W; Emerson M; Cicala C; Page CP
    Eur J Pharmacol; 1994 Oct; 264(2):183-90. PubMed ID: 7851481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
    Sinha U; Ku P; Malinowski J; Zhu BY; Scarborough RM; Marlowe CK; Wong PW; Lin PH; Hollenbach SJ
    Eur J Pharmacol; 2000 Apr; 395(1):51-9. PubMed ID: 10781674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition by Argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin.
    Lunven C; Gauffeny C; Lecoffre C; O'Brien DP; Roome NO; Berry CN
    Thromb Haemost; 1996 Jan; 75(1):154-60. PubMed ID: 8713795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological effects of a novel recombinant hirudin, CX-397, in vivo and in vitro: comparison with recombinant hirudin variant-1, heparin, and argatroban.
    Komatsu Y; Inoue Y; Goto Y; Fukazawa T; Hayashi H
    Thromb Haemost; 1999 Feb; 81(2):250-5. PubMed ID: 10064001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
    Hérault JP; Bernat A; Gaich C; Herbert M
    Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of thrombin inhibitors and a glycoprotein IIb/IIIa receptor antagonist in an ex vivo human experimental thrombosis model.
    Zokai K; Piazolo L; Harenberg J
    Semin Thromb Hemost; 2001 Oct; 27(5):531-6. PubMed ID: 11668424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet aggregation induced in vitro by rabbit plasma clot-associated thrombin, and its inhibition by thrombin inhibitors.
    Gandossi E; Lunven C; Gauffeny C; Roome NO; Berry CN
    Thromb Haemost; 1998 Nov; 80(5):840-4. PubMed ID: 9843181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific thrombin inhibitors in vivo.
    Fitzgerald D
    Ann N Y Acad Sci; 1994 Apr; 714():41-52. PubMed ID: 8017791
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
    Pehrsson S; Johansson K; Kjaer M; Elg M
    Thromb Haemost; 2010 Dec; 104(6):1242-9. PubMed ID: 20806126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a multifunctional staphylokinase variant with thrombin inhibition and antiplatelet aggregation activities produced from salt-inducible E. coli GJ1158.
    Kumar A; Pulicherla KK; Mayuren C; Kotra S; Rao KR
    Can J Physiol Pharmacol; 2013 Oct; 91(10):839-47. PubMed ID: 24144055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin.
    Buchanan MR; Boneu B; Ofosu F; Hirsh J
    Blood; 1985 Jan; 65(1):198-201. PubMed ID: 3965047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of coagulation and thrombin-induced platelet activities by a synthetic dodecapeptide modeled on the carboxy-terminus of hirudin.
    Jakubowski JA; Maraganore JM
    Blood; 1990 Jan; 75(2):399-406. PubMed ID: 2294999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies for inhibiting the effects of thrombin.
    Harker LA
    Blood Coagul Fibrinolysis; 1994 Jan; 5 Suppl 1():S47-58; discussion S59-64. PubMed ID: 8186356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombin inhibitors suppress the thrombin-thrombomodulin-mediated generation of activated protein C.
    Linder R; Blombäck M; Egberg N; Grip L
    Thromb Res; 1999 Jul; 95(2):117-25. PubMed ID: 10418800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative antithrombotic potencies of direct thrombin inhibitors and low-molecular-weight heparins in an ex vivo human experimental thrombosis model.
    Harenberg J; Zokai K; Piazolo L; Fenyvesi T; Jörg I
    Semin Thromb Hemost; 2002 Aug; 28(4):379-82. PubMed ID: 12244485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits.
    Carter CJ; Kelton JG; Hirsh J; Cerskus A; Santos AV; Gent M
    Blood; 1982 Jun; 59(6):1239-45. PubMed ID: 7082826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet deposition induced by severely damaged vessel wall is inhibited by a boroarginine synthetic peptide with antithrombin activity.
    Badimon JJ; Weng D; Chesebro JH; Fuster V; Badimon L
    Thromb Haemost; 1994 Apr; 71(4):511-6. PubMed ID: 8052972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of thrombin inhibitors on the thrombin-induced activation of human blood platelets.
    Markwardt F; Hoffmann A; Stürzebecher J
    Haemostasis; 1983; 13(4):227-33. PubMed ID: 6618289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.